Item 5.02 Departure of Directors or Principal Officers; Election of Directors;
Appointment of Principal Officers; Compensatory Arrangements of Certain
Officers.
Effective as of April 11, 2022, the Board of Directors of ALX Oncology Holdings
Inc. (the "Company") appointed Dr. Itziar Canamasas to its Board of Directors
and increased the size of its Board of Directors from six to seven directors in
connection with her appointment. The appointment was made based upon the
recommendation of the Corporate Governance and Nominating Committee of the
Company's Board of Directors. Dr. Canamasas has been designated as a Class II
director for a term expiring at the Company's 2022 Annual Meeting of
Stockholders.
Dr. Canamasas currently serves as the Head of Oncology Europe, Middle East and
Africa at Bayer AG. During her 20 plus years at Bayer, Dr. Canamasas has held
various oncology leadership positions with expertise focused on global
commercialization, strategic life-cycle development and corporate strategy,
including roles as Vice President of Global Marketing Oncology and Managing
Director of Bayer Limited. Dr. Canamasas is also the Organizational Development
Director for the Ambassador Program at the Healthcare Businesswomen's
Association (HBA). Dr. Canamasas holds an M.S. in Biology with distinction from
the Universitat de Barcelona and a Ph.D. in Cancer Genetics from the University
of Mainz.
In accordance with the Company's outside director compensation policy (the
"policy") and in connection with her appointment on April 11, 2022, Dr.
Canamasas was automatically granted an initial award of stock options to
purchase 24,009 shares of the Company's common stock (the "Initial Award"). The
Initial Award is scheduled to vest in equal installments as to one thirty-sixth
of the shares subject to the Initial Award on a monthly basis following the
Initial Award's grant date, on the same day of the month as the grant date,
subject to continued services to the Company through the applicable vesting
date. Dr. Canamasas shall also be entitled to annual cash compensation and
equity awards under the terms of the policy. In addition, the Company entered
into an indemnification agreement with Dr. Canamasas in the same form as the
Company's other directors.
There are no arrangements or understandings between Dr. Canamasas and any other
person pursuant to which she was selected to serve on the Company's Board of
Directors. There are no transactions in which the Company or any of its
subsidiaries is a party and in which Dr. Canamasas has a material interest
subject to disclosure under Item 404(a) of Regulation S-K.
On April 12, 2022, the Company, issued a press release announcing the
appointment of Dr. Canamasas to its Board of Directors effective as of April 11,
2022. A copy of this press release is furnished as Exhibit 99.1 to this Current
Report on Form 8-K and is incorporated herein by reference.
Exhibit
Number Description
99.1 Press Release dated April 12, 2022
104 Cover Page Interactive Data File (formatted as Inline XBRL)
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses